Total: $1,405.57M

Company
(Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Aradigm
Corp.
(ARDM)

Private placement of Series A convertible preferred stock

2S

$48.4

Aradigm raised $48.4M through the sale of 2M shares; investors were led by New Enterprise Associates, and included Camden Partners Inc., Castle Creek Partners and Domain Public Equity Partners (12/13)

Axonyx Inc.
(AXYX)

Private placement of common stock and warrants

W for 0.98S

$6.4

Axonyx raised $6.4M through the sale of common stock and warrants to a group of accredited investors; the stock was purchased at $3.26 per share; buyers also received two-year warrants to purchase an additional 985,000 shares at $3.91 per share (12/6)

Bioject
Medical
Technologies
Inc.
(BJCT)

Private placement of common stock

0.35S

$3.85

Bioject raised $3.85M in a private placement; Leerink, Swann & Co. acted as placement agent (12/20)

Cephalon
Inc.
(CEPH)

Private placement of convertible notes

ND

$500

Cephalon placed $500M of 2.5% notes; the agreement was managed by Credit Suisse First Boston (12/6)

Columbia
Laboratories
Inc.
(AMEX:
COB)

Private placement of common stock

1.12S

$2.97

Columbia raised $2.97M through a private sale of 1.12M shares; Acqua Wellington, Curran Partners and John Curran Affiliates, EGS Partners, Hillhouse Capital, Irvine Capital and Knott Partners participated in the financing (12/12)

ConjuChem
Inc.
(Canada;
TSE:CJM)

Private placement of a convertible note

ND

C$30 (US$19)

ConjuChem entered into an agreement with Baker/Tisch Capital, securing US$19M of financing via a convertible note (12/7)

Corixa Corp.
(CRXA)

Equity line of credit

ND

Corixa secured a $75M equity line of credit with BNY Capital Markets Inc. (12/5)

Cubist Pharm-
aceuticals
Inc.
(CBST)

Private placement of convertible subordinated notes

ND

$40

Cubist raised another $40M when purchasers of $125M in notes in October exercised their option for additional notes, bringing the total raised to $165M (12/26)

EntreMed
Inc.
(ENMD)

Private placement of common stock and warrants

2.9S and W for 0.73S

$22.6

EntreMed raised $22.6M in a private placement (12/19)

Epimmune
Inc.
(EPMN)

Private placement of common stock

2S

$5

Epimmune raised $5M with the placement of 2M shares; investors included the State of Wisconsin Investment Board, International Biotechnology Trust, Genencor International Inc., Peter Allard and Ted Greene (12/19)

GenVec Inc.
(GNVC)

Private placement of common stock

3.6S

$13

GenVec raised $13M by placing about 3.6M shares to funds managed by HealthCare Ventures (12/26)

GlycoGenesys
Inc.
(GLGS)

Private placement of common stock

4.2S and W

$5.3

GlycoGenesys raised $5.3M in net proceeds from institutional and accredited investors (12/21)

Heska Corp.
(HSKA)

Private placement of common stock

7.8S

$6

Heska raised $6M in a private placement; investors were led by the State of Wisconsin Investment Board (12/20)

Hollis-Eden
Pharmaceu-
ticals
Inc.
(HEPH)

Private placement of common stock and warrants

1.3S and W for 0.13S

$11.5

Hollis-Eden raised $11.5M through the sale of about 1.3M shares at $9 per share and warrants to purchase up to 128,000 shares of common stock (12/13)

IGEN Inter-
national
Inc.
(IGEN)

Private placement of common stock

1.02S

$30

IGEN completed a $30M private placement of 1.02M shares to Acqua Wellington Private Placement Fund Ltd. and Acqua Wellington Opportunity I Ltd. (12/12)

Interneuron
Pharmaceu-
ticals
Inc.
(IPIC)

Private placement of common stock

3.125S

$25

Interneuron raised $25M by placing 3.125M shares to institutional investors; Legg Mason Wood Walker acted as placement agent

Invitrogen
Corp.
(IVGN)

Private placement of convertible subordinated notes

ND

$500

Invitrogen sold $500M in notes in a private placement (12/6)

Martek
Biosciences
Corp.
(MATK)

Private placement of common stock

1.2S

$22.5

Martek placed about 1.2M shares at $19.25 each; Adams, Harkness & Hill served as placement agent (12/18)

NeoThera-
peutics
Inc.
(NEOT)

Private placement of common stock

0.77S

$2.95

NeoTherapeutics placed 0.77M shares, raising $2.95M; Ladenburg Thalmann & Co. Inc. and Cantor Fitzgerald & Co. served as placement agents (12/12)

Orphan
Medical
Inc.
(ORPH)

Private placement of common stock

1.7S

$14.1

Orphan Medical raised $14.1M in a private placement of 1.7M shares to Alta Bio Pharma Partners LP; funds were managed by current investors OrbiMed Advisors LLC and Medical Strategy; Thomas Weisel Partners LLC acted as Orphan's agent and financial adviser in the transaction (12/10)

Ribozyme
Pharmaceu-
ticals Inc.
(RZYM)

Private placement of common stock and warrants

0.75S and W for 0.075S

$3

Ribozyme received an additional $3M in its private placement begun in November, bringing the total raised to $12.5M; ABN AMRO Inc. served as financial adviser and placement agent (12/28)

Senesco
Technol-
ogies Inc.
(OTC BB:
SENO)

Private placement of common stock and warrants

1.1S and W for 1S

$2

Senesco completed a $2M placement with Stanford Venture Capital Holdings Inc. (12/5)

Sepracor
Inc.
(SEPR)

Private placement of convertible subordinated notes

ND

$100

Sepracor raised another $100M in a private placement conducted in November; the initial purchaser exercised in full the $100M overallotment option (12/21)

Visible
Genetics
Inc.
(VGIN)

Private placement of common stock

2.6S

$22

Visible Genetics raised $22M in a private placement (12/26)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange